MUTUAL NON-DISCLOSURE AGREEMENTMutual Non-Disclosure Agreement • December 12th, 2014 • Otsuka Holdings Co., Ltd. • Pharmaceutical preparations • California
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of MAY 13, 2013 (the “Effective Date”), governs the disclosure of information by and between AVANIR PHARMACEUTICALS, INC., a Delaware corporation, with offices located at 20 Enterprise, Suite 200, Aliso Viejo, California, 92656, and OTSUKA PHARMACEUTICAL CO. LTD. a JAPANESE CORPORATION, with offices located at 2-9, KANDA TSUKASA-MACHI, CHIYODA-KU, TOKYO 101-8535, JAPAN (each a “party” and sometimes collectively referred to as the “parties” to this Agreement).
FIRST AMENDMENT TO NON-DISCLOSURE AGREEMENTNon-Disclosure Agreement • December 12th, 2014 • Otsuka Holdings Co., Ltd. • Pharmaceutical preparations
THIS FIRST AMENDMENT to the Non-Disclosure Agreement (“Amendment”) is effective as of JULY 16, 2013, by and between AVANIR PHARMACEUTICALS, INC. (“Avanir”) and OTSUKA PHARMACEUTICAL CO. LTD. (“Company”). Hereafter, each of Avanir and Company may also be referred to as a “party” and sometimes collectively referred to as the “parties”.
SECOND AMENDMENT TO NON-DISCLOSURE AGREEMENTNon-Disclosure Agreement • December 12th, 2014 • Otsuka Holdings Co., Ltd. • Pharmaceutical preparations
THIS SECOND AMENDMENT to the Non-Disclosure Agreement (“Amendment”) is effective as of SEPTEMBER 2, 2014, by and between AVANIR PHARMACEUTICALS, INC. (“Avanir”) and OTSUKA PHARMACEUTICAL CO. LTD. (“Company”). Hereafter, each of Avanir and Company may also be referred to as a “party” and sometimes collectively referred to as the “parties”.
